The Petitions of the Week column highlights a selection of cert petitions recently filed in the Supreme Court. A list of all petitions we’re watching is available here. Litigants in federal courts may unwittingly find themselves in a “finality trap,” a tricky procedural scenario in which they are u
Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibitor,.
Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Boehringer Ingelheim and Carelon Research have conducted the first large-scale U.S. validation of a new AI-driven tool for chronic kidney disease (CKD) The Klinrisk model predicted disease progression in over 80% of individuals at all stages of the disease, based on data from a diverse population of over 4 million U.S. adults Validated tools to […]
/PRNewswire/ Boehringer Ingelheim and Carelon Research have conducted a validation study of the Klinrisk model, a machine-learning tool developed to predict.